Our readers hunger for context and analysis of major developments in the industry. We work hard to deliver such insights in all of our daily reports. Yet we aim to go deeper into stories with additional feature articles and special reports.
As the biotech advances its lead antiviral drug to Phase III development, Chimerix has tapped a veteran of one of the most high-profile pharma R&D programs in the world.
Bristol-Myers Squibb was having a very bad day today. As its stock was falling in the wake of the news that its $2.5 billion hep C drug may not be worth $2.50, one of its executives was charged with insider trading ahead of three key acquisitions, according to a report from Bloomberg.
The two research powerhouses will conduct a drug-drug interaction study.
The news that two more hepatitis C patients had relapsed after they stopping taking an experimental medication in a tiny study wouldn't normally be the cause for considerable angst in the biotech...
Thorny data now threaten what some industry commentators have called a market bubble for all-oral regimens against hepatitis C. Gilead Sciences ($GILD) revealed that certain patients who had not...
At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech's hepatitis C programs by making it clear that he was angling for
Gilead Sciences ($GILD) received its first bonus from the monster $10.8 billion deal to acquire Pharmasset ($VRUS) after CSO Norbert Bischofberger told analysts yesterday evening that PSI-7977
The news of the Bristol-Myers/Inhibitex deal couldn't have been better timed. With the biotech world converging on San Francisco today for the annual JP Morgan confab, there's nothing like a
Proving once again that hepatitis C is the hottest disease in biotech right now, Bristol-Myers Squibb ($BMY) has stepped up to the deal table with a $2.5 billion pact to buy out Inhibitex ($INHX), a